Author: Alavi, Mehran; Asare-Addo, Kofi; Nokhodchi, Ali
Title: Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus Cord-id: 3eq2qjjm Document date: 2020_12_7
ID: 3eq2qjjm
Snippet: The outbreak of a novel strain coronavirus as the causative agent of COVID-19 pneumonia, first identified in Wuhan, China in December 2019, has resulted in considerable focus on virulence abilities of coronavirus. Lectins are natural proteins with the ability to bind specific carbohydrates related to various microorganisms, including viruses, bacteria, fungi and parasites. Lectins have the ability to agglutinate and neutralize these pathogeneses. The delivery of the encapsulated antiviral agents
Document: The outbreak of a novel strain coronavirus as the causative agent of COVID-19 pneumonia, first identified in Wuhan, China in December 2019, has resulted in considerable focus on virulence abilities of coronavirus. Lectins are natural proteins with the ability to bind specific carbohydrates related to various microorganisms, including viruses, bacteria, fungi and parasites. Lectins have the ability to agglutinate and neutralize these pathogeneses. The delivery of the encapsulated antiviral agents or vaccines across the cell membrane can be possible by functionalized micellar and liposomal formulations. In this mini-review, recent advances and challenges related to important lectins with inhibition activities against coronaviruses are presented to obtain a novel viewpoint of microformulations or nanoformulations by micellar and liposomal cell-binding carriers.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adefovir dipivoxil: 1
- acute respiratory syndrome and loading antibody: 1
- acute respiratory syndrome and long history: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory syndrome and low bioavailability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and low degradation: 1
- adaptive immune response and lopinavir ritonavir: 1
- adaptive immune response and low bioavailability: 1
- adaptive immune response and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adaptive immune response and lung infection prevention: 1
- adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adaptive immune response and macrophage monocyte: 1, 2, 3
- long history and lung infection: 1, 2
- long history and lung infection reduce: 1
- long history and lung injury: 1, 2
- lopinavir ritonavir and low bioavailability: 1
- lopinavir ritonavir and lung infection: 1, 2, 3, 4, 5, 6, 7, 8
- lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- lopinavir ritonavir and lung viral load: 1
Co phrase search for related documents, hyperlinks ordered by date